Compare TGLS & IRON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TGLS | IRON |
|---|---|---|
| Founded | 1984 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electronic Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.3B |
| IPO Year | 2011 | 2020 |
| Metric | TGLS | IRON |
|---|---|---|
| Price | $42.78 | $59.61 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 12 |
| Target Price | $67.50 | ★ $101.67 |
| AVG Volume (30 Days) | 512.2K | ★ 582.0K |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.38% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 3.42 | N/A |
| Revenue | ★ $370,984,000.00 | N/A |
| Revenue This Year | $13.46 | N/A |
| Revenue Next Year | $9.77 | $101.57 |
| P/E Ratio | $12.75 | ★ N/A |
| Revenue Growth | ★ 17.98 | N/A |
| 52 Week Low | $40.72 | $30.82 |
| 52 Week High | $90.34 | $99.50 |
| Indicator | TGLS | IRON |
|---|---|---|
| Relative Strength Index (RSI) | 37.07 | 38.62 |
| Support Level | $40.72 | $57.81 |
| Resistance Level | $54.59 | $64.00 |
| Average True Range (ATR) | 2.04 | 2.89 |
| MACD | 0.00 | 0.06 |
| Stochastic Oscillator | 30.68 | 16.99 |
Tecnoglass Inc is a manufacturer of hi-spec architectural glass and windows for residential and commercial construction industries, operating through its direct and indirect subsidiaries. Its product offerings include tempered glass, laminated glass, thermo-acoustic glass, sliding windows, projecting windows, guillotine windows, sliding doors, loating facades, automatic doors, bathroom dividers, and commercial display windows, among others. The company has one operating segment, Architectural Glass and Windows, which is also its reporting segment. Geographically, the company generates maximum revenue from its customers in the United States, followed by Colombia, Panama, and other regions.
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs) including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.